Göttingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences

Sereda, Michael Werner, Prof. Dr.



  • 2007 Group leader ”Molecular and Translational Neurology“, Max Planck Institute of Experimental Medicine
  • 2008 Board certification in Neurology (Facharzt für Neurologie)
  • 2008 Attending Neurologist and Head Neurogenetics Outpatients Clinic, Dept. of Clinical Neurophysiology, University of Göttingen (UMG)
  • 2010 Associate Professorship “Neurology and Neurogenetics” (Habilitation)
  • 2012 DFG-Heisenberg Professorship “Hereditary Neuropathies", Dept. of Clinical Neurophysiology, University of Göttingen, UMG
  • 2017 Tenured Professorship of Neurology, Dept. of Clinical Neurophysiology, UMG



Major Research Interests

We pursue a basic research interest in glia cell biology, axon-glia interaction and mechanisms of diseases of the peripheral nervous system (PNS). We have generated a transgenic rat model of the most frequent human neuropathy, Charcot-Marie-Tooth disease type 1A (CMT1A). This disease is associated with a partial duplication of chromosome 17 which leads to an overexpression of the tetraspan protein PMP22. Transgenic “CMT rats” expressing additional copies of this gene share
characteristic clinical features of the human disease, including muscle weakness, reduced nerve conduction velocities, and marked Schwann cell hypertrophy resulting in onion bulb formation. The CMT rat allows a better understanding of the cellular disease mechanism operating in human CMT1A, and is helpful in the analysis of modifier genes, epigenetic factors, and in the evaluation of experimental treatment strategies. In an attempt to translate findings from the animal model to humans we were able to identify biomarkers of disease severity in the skin of CMT1A patients, which could already be validated in patients from across Europe. Currently, within CMT-NET, a national BMBF funded network on rare diseases coordinated by Prof. Sereda, we aim at transferring our results from skin to easily accessible blood samples from CMT patients, which would facilitate the performance of clinical trials in the near future.


Homepage Department/Research Group

http://www.em.mpg.de/index.php?id=122&L=1/



Selected Recent Publications

  • Fledrich R, Abdelaal T, Rasch L, Bansal V, Schütza V, Brügger B, Lüchtenborg C, Prukop T, Stenzel J, Rahman RU, Hermes D, Ewers D, Möbius W, Ruhwedel T, Katona I, Weis J, Klein D, Martini R, Brück W, Müller WC, Bonn S, Bechmann I, Nave KA, Stassart RM, Sereda MW (2018) Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat Commun. 9(1):3025
  • Fledrich R, Mannil M, Leha A, Ehbrecht C, Solari A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Schnizer TJ, Prukop T, Garcia-Angarita N, Czesnik D, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Walter MC, Triaal C, Hogrel JY, Dubourg O, Schenone A, Baets J, De Jonghe P, Shy ME, Horvath R, Pareyson D, Seeman P, Young P, Sereda MW (2017) Biomarkers predict outcome in Charcot- Marie-Tooth disease 1A. J Neurol Neurosurg Psychiatry. 88, 941-9522
  • Quintes S, Brinkmann BG, Ebert M, Fröb F, Kungl T, Arlt FA, Tarabykin V, Huylebroeck D, Meijer D, Suter U, Wegner M, Sereda MW, Nave KA (2016) Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair. Nat Neurosci.; 19(8):1050-9. doi: 10.1038/nn.4321. Epub 2016 Jun 13.
  • Epplen DB, Prukop T, Nientiedt T, Albrecht P, Arlt FA, Stassart RM, Kassmann CM, Methner A, Nave KA, Werner HB, Sereda MW (2015) Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease. Ann Clin Transl Neurol. 2, 787-796
  • Pehlivan D, Beck CR, Okamoto Y, Harel T, Akdemir ZH, Jhangiani SN, Withers MA, Goksungur MT, Carvalho CM, Czesnik D, Gonzaga-Jauregui C, Wiszniewski W, Muzny DM, Gibbs RA, Rautenstrauss B, Sereda MW, Lupski JR (2016) The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy. Genet Med.;18(5):443-51. doi: 10.1038/gim.2015.124.PMID: 26378787
  • Prukop T, Epplen DB, Nientiedt T, Wichert SP, Fledrich R, Stassart RM, Rossner MJ, Edgar JM, Werner HB, Nave KA, Sereda MW (2014) Progesterone Antagonist Therapy in a Pelizaeus-Merzbacher Mouse Model. Am J Hum Genet. 94, 533-546
  • Mannil M, Solari A, Leha A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Walter MC, Rautenstrauss B, Schnizer TJ, Schenone A, Seeman P, Kadian C, Schreiber O, Angarita NG, Fabrizi GM, Gemignani F, Padua L, Santoro L, Quattrone A, Vita G, Calabrese D; CMT-TRIAAL/CMT-TRAUK Group, Young P, Laurà M, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Shy ME, Reilly MM, Pareyson D, Sereda MW (2014) Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscul Disord. 24, 1003-1017
  • Fledrich R, Stassart RM, Klink A, Rasch LM, Prukop T, Haag L, Czesnik D, Kungl T, Abdelaal TA, Keric N, Stadelmann C, Brück W, Nave KA, Sereda MW (2014) Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med. 20, 1055-1061
  • Fledrich R, Schlotter-Weigel B, Schnizer TJ, Wichert SP, Stassart RM, Meyer Zu Hörste G, Klink A, Weiss BG, Haag U, Walter MC, Rautenstrauss B, Paulus W, Rossner MJ, Sereda MW (2012) A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain 135, 72-87
  • Fledrich R, Stassart RM, Sereda MW (2012) Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease. Br Med Bull. 102, 89-113